Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2019, Article ID 2987461, 4 pages
https://doi.org/10.1155/2019/2987461
Case Report

Acute Deterioration of Pulmonary Arterial Hypertension (PAH) in a Patient with Neurofibromatosis Type 1 (NF1)

1Department of Cardiovascular Medicine, Kitakyushu Municipal Yahata Hospital, 2-6-2 Okura, Yahatahigashi-ku, Kitakyushu 805-8534, Japan
2Department of Internal Medicine, Kitakyushu Municipal Yahata Hospital, 2-6-2 Okura, Yahatahigashi-ku, Kitakyushu 805-8534, Japan

Correspondence should be addressed to Seiya Tanaka; moc.em@akanatayas

Received 13 March 2019; Accepted 3 June 2019; Published 22 July 2019

Academic Editor: Nurten Sayar

Copyright © 2019 Seiya Tanaka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Theos, B. R. Korf, American College of Physicians, and American Physiological Society, “Pathophysiology of neurofibromatosis type 1,” Annals of Internal Medicine, vol. 144, no. 11, pp. 842–849, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. R. E. Ferner, “Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective,” Lancet Neurology, vol. 6, no. 4, pp. 340–351, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. D. R. Stewart, J. D. Cogan, M. R. Kramer et al., “Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy?” Chest, vol. 132, no. 3, pp. 798–808, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. P. B. Poble, J. C. Dalphin, and B. Degano, “Severe dyspnea in a patient with neurofibromatosis type 1,” Respiratory Medicine Case Reports, vol. 22, pp. 74–76, 2017. View at Publisher · View at Google Scholar · View at Scopus
  5. U. Chaddha, I. Puscas, A. Prosper, S. Ganesh, and B. Yaghmour, “A 63-year-old woman with neurofibromatosis type 1 and pulmonary hypertension with worsening hypoxemia,” Chest, vol. 152, no. 4, pp. e89–e93, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Simonneau, I. M. Robbins, M. Beghetti et al., “Updated clinical classification of pulmonary hypertension,” Journal of the American College of Cardiology, vol. 54, no. 1, pp. S43–S54, 2009, Suppl. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Galiè, M. Humbert, J.-L. Vachiery et al., “2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension,” Revista Española de Cardiología (English Edition), vol. 69, no. 2, p. 177, 2016. View at Publisher · View at Google Scholar
  8. D. Montani, F. Coulet, B. Girerd et al., “Pulmonary hypertension in patients with neurofibromatosis type I,” Medicine (Baltimore), vol. 90, no. 3, pp. 201–211, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. D. A. Stumpf, J. F. Alksne, J. F. Annegers, S. S. Brown, P. M. Conneally, and D. Housman, “National Institutes of Health Consensus Development Conference Statement. Bethesda, Md., USA, July 13-15, 1987,” Neurofibromatosis, vol. 1, no. 3, pp. 172–178, 1988. View at Google Scholar
  10. M. Gomberg-Maitland, M. L. Maitland, R. J. Barst et al., “A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension,” Clinical Pharmacology and Therapeutics, vol. 87, no. 3, pp. 303–310, 2009. View at Publisher · View at Google Scholar · View at Scopus